These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23877633)

  • 1. (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy.
    Carkaci S; Sherman CT; Ozkan E; Adrada BE; Wei W; Rohren EM; Mawlawi OR; Ueno NT; Buchholz TA; Yang WT
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1809-16. PubMed ID: 23877633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
    Jacene HA; Youn T; DiPiro PJ; Hu J; Cheng SC; Franchetti Y; Shah H; Bellon JR; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth J; Yeh E; Overmoyer B;
    Clin Breast Cancer; 2019 Apr; 19(2):146-155. PubMed ID: 30584057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated tumor-to-liver uptake ratio (TLR) from
    Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased FDG uptake in breast cancer is associated with prognostic factors.
    Sanli Y; Kuyumcu S; Ozkan ZG; Işik G; Karanlik H; Guzelbey B; Turkmen C; Ozel S; Yavuz E; Mudun A
    Ann Nucl Med; 2012 May; 26(4):345-50. PubMed ID: 22359222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
    Kim JY; Lee SH; Kim S; Kang T; Bae YT
    Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study.
    Jin S; Kim SB; Ahn JH; Jung KH; Ahn SH; Son BH; Lee JW; Gong G; Kim HO; Moon DH
    J Surg Oncol; 2013 Feb; 107(2):180-7. PubMed ID: 22948739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
    Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
    AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.